NASDAQ: NXLNexalin Technology Inc Stock
$1.47+0.15 (+11.36%)
Updated Apr 18, 2024
NXL Price
$1.47
Fair Value Price
$0.02
Market Cap
$10.93M
52 Week Low
$0.25
52 Week High
$3.40
P/E
-2.33x
P/B
3.41x
P/S
26.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$110.75k
Earnings
-$4.65M
Gross Margin
76.8%
Operating Margin
-4,162.49%
Profit Margin
-4,197.6%
Debt to Equity
0.13
Operating Cash Flow
-$4M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NXL Overview
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NXL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NXL ($1.47) is overvalued by 6,043.7% relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NXL ($1.47) is not significantly undervalued (6,043.7%) relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NXL due diligence checks available for Premium users.
Be the first to know about important NXL news, forecast changes, insider trades & much more!
NXL News
Valuation
NXL fair value
Fair Value of NXL stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
$0.02
Overvalued by
6,043.70%
NXL ($1.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NXL ($1.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NXL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NXL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.33x
Industry
28.61x
Market
41.33x
NXL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.41x
Industry
3.63x
NXL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NXL's financial health
Profit margin
Revenue
$20.5k
Net Income
-$780.7k
Profit Margin
-3,801.5%
NXL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NXL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6M
Liabilities
$425.3k
Debt to equity
0.13
NXL's short-term assets ($3.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NXL's short-term assets ($3.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NXL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
$1.2M
Financing
$0.0
NXL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NXL vs Medical Device Stocks
Nexalin Technology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.